News | May 28, 2025
Granules India posts Q4 FY25 PAT at Rs. 152 Cr
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Alembic Pharmaceuticals commissions new facility at Pithampur
Subscribe To Our Newsletter & Stay Updated
